CareDx, Inc. (NASDAQ:CDNA) Given Average Rating of “Hold” by Brokerages

CareDx, Inc. (NASDAQ:CDNA) has received a consensus rating of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $27.3333.

Several equities research analysts have recently commented on CDNA shares. BTIG Research upped their price target on CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price for the company. in a research note on Tuesday, January 6th. Weiss Ratings downgraded shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, February 27th. Finally, Wells Fargo & Company boosted their price target on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th.

Insider Transactions at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the transaction, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at approximately $12,641,089.80. This represents a 3.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 29,636 shares of company stock worth $625,949. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP purchased a new position in CareDx in the fourth quarter worth $25,000. FNY Investment Advisers LLC acquired a new position in shares of CareDx during the 3rd quarter worth $31,000. State of Alaska Department of Revenue purchased a new position in shares of CareDx in the 3rd quarter valued at about $43,000. Meeder Asset Management Inc. acquired a new stake in shares of CareDx in the fourth quarter valued at about $79,000. Finally, Quantbot Technologies LP purchased a new stake in CareDx during the third quarter worth about $89,000.

CareDx Stock Performance

Shares of CDNA opened at $17.36 on Wednesday. The company has a market capitalization of $889.18 million, a price-to-earnings ratio of -43.40 and a beta of 2.52. CareDx has a fifty-two week low of $10.96 and a fifty-two week high of $21.49. The firm has a 50-day simple moving average of $18.83 and a 200-day simple moving average of $17.60.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.12). CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. The company had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $102.76 million. During the same period in the prior year, the company earned $0.18 earnings per share. The firm’s revenue was up 25.2% on a year-over-year basis. Equities research analysts forecast that CareDx will post -0.9 EPS for the current year.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.